ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
30 announcements with these filters
Standalone revenue +28% Q2, +21% H1; PAT +131% Q2. EBITDA margin 35%, gross margin 78%. H1 consolidated PAT boosted by one-time Africa loan gain.
Hester Biosciences Ltd reported revenue from operations of ₹97.9 Cr (+37.9% YoY) and net profit of ₹20.6 Cr (+44.1% YoY) for Q2 FY27.
Hester Biosciences scheduled its Board of Directors meeting for 5 November 2026 to review unaudited H1 FY27 results. No decisions or figures are reported yet.
Hester Biosciences disclosed Independent Director Mr. Ameetkumar Desai ceased his role on 27 October 2026 upon completing his first tenure. He opted not to seek re-appointment.
Hester Biosciences reported shareholding data for the quarter ending September 2026. Two promoters were reclassified as public shareholders, reducing the promoter holding.
Hester Biosciences' board approved a ₹1.05 Cr stake in SLYCE AGRI WORLD LLP for captive solar power generation. The PPA secures captive electricity supply to the company.
Hester Biosciences Limited received shareholder approval to reclassify Mr. Ravin Gandhi and Ms. Bela Gandhi from the 'Promoter' category to the 'Public' category.
Hester Biosciences Limited shareholders approved the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public' category via postal ballot.
Hester Biosciences Ltd received an upgrade in its long-term and short-term bank facility credit ratings from CARE Ratings.
Hester Biosciences is conducting a postal ballot to seek shareholder approval for the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public'.
Hester Biosciences Limited has launched a dedicated interactive digital microsite for its 39th Annual Report for FY 2025-26 to enhance stakeholder accessibility and engagement.
Hester Biosciences delivered strong standalone Q1 growth with revenues up 14% and profit up 88%. Consolidated profit surged 459% due to an INR 853.49 million exceptional gain from a loan amendment.
Hester Biosciences reported Q1 FY27 results, with standalone revenue up 14% to ₹72.60 Crore and profit growing 88% to ₹14.71 Crore.
Hester Biosciences Ltd reported revenue from operations of ₹77.2 Cr (-8.2% YoY) and net profit of ₹96.7 Cr (+459.0% YoY) for Q1 FY27.
Hester Biosciences received no-objection letters from NSE and BSE for the re-classification of Mr. Ravin Gandhi and Ms. Bela Gandhi from Promoter to Public category.
Hester Biosciences has scheduled a board meeting for 30 July 2026 to consider unaudited standalone and consolidated financial results for the quarter ended 30 June 2026.
Hester Biosciences Limited successfully concluded its 39th Annual General Meeting. Shareholders approved all resolutions, including the adoption of financial statements and the declaration of dividend.
Hester Biosciences exited its 11% stake in Texas Lifesciences for Rs. 2.3 Crore. The company now holds nil investment in the entity.
Hester Biosciences corrected its AGM notice, updating the Executive Director’s gross salary to INR 10 lakh per month. The amendment rectifies a typographical error in the original notice.
Hester Biosciences modified its corporate guarantee for subsidiary Hester Africa's loan, now reduced to USD 5 million. The amendment improves subsidiary liquidity and debt servicing positions.
Hester Biosciences submitted reclassification applications to BSE and NSE for two promoters moving to the public category. This transition follows regulatory filings made on May 19, 2026.
Hester Biosciences submitted its Annual Secretarial Compliance Report for the year ended March 31, 2026. The report confirms overall regulatory adherence with no material non-compliances observed.
Hester Biosciences reported Q4 and FY26 results with consolidated revenue growth of 22% and substantial PAT increase. Strategy focuses on biologicals, capacity utilization, and African market expansion.
Hester Biosciences reported FY26 consolidated revenue of ₹3,325.99 Mn (₹332.60 Cr) and PAT of ₹57.48 Cr, focusing on global expansion in animal and poultry vaccines.
Hester Biosciences delivered a strong Q3 FY26 with standalone revenue up 12% and PAT up 140%, driven by robust Poultry Healthcare performance and operational leverage despite Animal Healthcare headwinds.
Hester Biosciences Ltd reported revenue from operations of ₹100.1 Cr (+22.2% YoY) and net profit of ₹16.5 Cr (+1000.0% YoY) for Q4 FY26.
Mr. Ravin Gandhi and Ms. Nina Gandhi resigned from Hester Biosciences' board effective May 12, 2026. The departures follow personal commitments and professional time constraints.
Hester Biosciences scheduled a board meeting for 15 May 2026. Directors will consider annual audited financial results and potential dividend declarations for the 2025-26 fiscal year.
Hester Biosciences Limited submitted its quarterly confirmation certificate for the period ended 31 March 2026. The filing confirms compliance with SEBI regulations regarding the dematerialisation and rematerialisation of securities by its registrar, MUFG Link Intime India.
Hester Biosciences Limited confirmed it is not classified as a 'Large Corporate' under SEBI's framework for the financial year. As of March 31, 2026, the company reported outstanding long-term borrowings of ₹12.78 Crore and maintains a 'BBB+: Stable' credit rating from CARE Ratings.